About chornixadm

This author has not yet filled in any details.
So far chornixadm has created 24 blog entries.

Madappa N. Kundranda, MD, PhD. Director, Gastrointestinal Oncology Program, Adjunct Assistant Professor, University of Texas MD Anderson Cancer Center,Banner MD Anderson, Arizona.

Experts on Chronix Biomedical CNI Monitor test. Testing for drug efficacy. #TheTurningPointInCancerFight

By | July 10th, 2017|Video|0 Comments

Early detection of cancer – why is it important?

The number of people diagnosed with tumors, especially malignant ones, is constantly increasing. There is also a rise in mortality rate due to delayed diagnosis and inappropriate treatment. Therefore, proper cancer diagnosis is very important. Early detection of a tumor makes it more probable that the patient will, finally, beat the cancer and recover. However, [...]

By | July 6th, 2017|Chronix news|0 Comments

Chronix ASCO 2017: Dr Glen Weiss

Experts on Chronix Biomedical CNI Monitor test. Testing for drug efficacy. #TheTurningPointInCancerFight

By | July 3rd, 2017|Video|0 Comments

It was the 5th year that Chronix Biomedical has been present at ASCO Annual Meeting in Chicago

This was the busiest ASCO conference yet for Chronix Biomedical. Chronix booth was visited by clinical trial oncologists, international cancer research...

By | June 22nd, 2017|Chronix news, Events|0 Comments

Chronix Biomedical reports positive interim pancreatic cancer data

Chronix Biomedical reports a positive interim analysis of its ongoing validation study of its Copy Number Instability (CNI)-based therapeutic monitoring test in pancreatic cancer. The study compares the accuracy of Chronix’s CNI-based test at predicting a clinical response, as early as after the first cycle of chemotherapy compared to CA19-9, a commonly used biomarker.

By | June 14th, 2017|Chronix news|0 Comments

Chronix Biomedical presents positive data on prognostic test in head/neck cancer study data at ASCO

Study finds CNI score to be a stronger predictor of time to recurrence in head and neck cancer than current method based on lymph node invasion. The study enrolled 54 patients undergoing surgery for this cancer type and evaluated the Chronix test as a predictor of time to progression in comparison with the current method based on the degree of tumour invasion of lymph nodes (pN status).

By | June 5th, 2017|Chronix news|0 Comments

Cell-free DNA for treatment monitoring and outcome predictor in head and neck cancer

Chronix Biomedical presents positive data on prognostic test in head/neck cancer study data at ASCO. Study finds CNI score to be a stronger predictor of time to recurrence in head and neck cancer than current method based on lymph node invasion.

By | June 5th, 2017|Peer-reviewed medical publications|0 Comments

Chronix Biomedical is pleased to be a sponsor of the PCRT annual meeting

Chronix Biomedical

Chronix looks forward to working with this team of international pancreatic cancer experts.

By | June 2nd, 2017|Chronix news|0 Comments

Chronix at the ASCO 2017 Annual Meeting

Chronix Biomedical

This is the third year that Chronix is presenting its study results at ASCO — this year’s results are from a blinded prospective study validating the use of a CNI Monitor blood test to predict the treatment outcome of patients undergoing immunotherapy.

By | June 2nd, 2017|Chronix news|0 Comments

Chronix ASCO 2017: Dr Tomislav Dragovich

Experts on Chronix Biomedical CNI Monitor test. Testing for drug efficacy. #TheTurningPointInCancerFight

By | May 26th, 2017|Video|0 Comments